Bausch + Lomb
Open
$15.63
Prev. Close
$15.63
High
$15.67
Low
$15.63
Market Snapshot
$5.43B
-15.1
-1.03
$4.83B
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,000 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Bausch + Lomb forecasts 2026 revenues of $5.42B-$5.52B and adjusted EBITDA of $1.01B-$1.06B, indicating robust growth in the ophthalmic products market.
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 13,000 full-time employees. The company went IPO on 2022-05-06. The company operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Recently from Cashu
Bausch + Lomb's Stock Plummets Amid Voluntary Recall Challenges and Investor Concerns
Bausch + Lomb Faces Challenges Amid Product Recall Bausch + Lomb, a prominent player in the eye care industry, encounters significant challenges following a recent voluntary recall of certain implanta…
Bausch + Lomb's Stock Declines Amid Voluntary Recall of Eye Lenses and Safety Concerns
Bausch + Lomb Faces Challenges Following Voluntary Recall of Eye Lenses Bausch + Lomb, a prominent player in the eye care industry, confronts significant challenges after announcing a voluntary recall…